pioglitazone has been researched along with Asthma, Bronchial in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 9.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 9.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| "This pilot study suggests limited efficacy for pioglitazone in the treatment of poorly controlled asthma in obesity, and also the potential for harm, given the weight gain in those assigned to active treatment, and the association between increased weight and worse outcomes in asthma." | 9.20 | A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. ( Black, K; DeSarno, M; Dixon, AE; Holguin, F; Lane, L; Subramanian, M, 2015) |
| "We compared the effectiveness of the PPAR-gamma agonist pioglitazone (PIO) to the established effectiveness of a glucocorticoid receptor agonist, dexamethasone (DEX), in a murine model of asthma induced by cockroach allergen (CRA)." | 7.74 | Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. ( Berlin, AA; Lukacs, NW; Narala, VR; Ranga, R; Reddy, RC; Smith, MR; Standiford, TJ, 2007) |
| "Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 5.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 5.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| "This pilot study suggests limited efficacy for pioglitazone in the treatment of poorly controlled asthma in obesity, and also the potential for harm, given the weight gain in those assigned to active treatment, and the association between increased weight and worse outcomes in asthma." | 5.20 | A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. ( Black, K; DeSarno, M; Dixon, AE; Holguin, F; Lane, L; Subramanian, M, 2015) |
| "Peroxisome proliferator-activated receptor-γ (PPARγ) agonist pioglitazone (PGZ) exhibits potential protective effects in asthma." | 3.88 | PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. ( Deng, W; Fang, P; Liu, Y; Meng, X; Shi, H; Sun, X; Wang, G; Yang, S; Zhang, Y, 2018) |
| " In this study, we used a mouse model of asthma to evaluate the effect of two PPARgamma agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease." | 3.75 | Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. ( Chae, HJ; Choe, YH; Kim, SR; Lee, KS; Lee, YC; Min, KH; Moon, H; Park, SJ; Yoo, WH, 2009) |
| "We compared the effectiveness of the PPAR-gamma agonist pioglitazone (PIO) to the established effectiveness of a glucocorticoid receptor agonist, dexamethasone (DEX), in a murine model of asthma induced by cockroach allergen (CRA)." | 3.74 | Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. ( Berlin, AA; Lukacs, NW; Narala, VR; Ranga, R; Reddy, RC; Smith, MR; Standiford, TJ, 2007) |
| " We have used a mouse model for asthma to determine the effect of PPARgamma agonists, rosiglitazone or pioglitazone, and PPARgamma on allergen-induced bronchial inflammation and airway hyperresponsiveness." | 3.73 | PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. ( Chai, OH; Hwang, PH; Kim, JS; Lee, KS; Lee, MK; Lee, YC; Park, SJ; Song, CH; Yi, HK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaler, M | 1 |
| Barochia, AV | 1 |
| Weir, NA | 1 |
| Cuento, RA | 1 |
| Stylianou, M | 1 |
| Roth, MJ | 1 |
| Filie, AC | 1 |
| Vaughey, EC | 1 |
| Nathan, SD | 1 |
| Levine, SJ | 1 |
| Meng, X | 1 |
| Sun, X | 1 |
| Zhang, Y | 1 |
| Shi, H | 1 |
| Deng, W | 1 |
| Liu, Y | 1 |
| Wang, G | 1 |
| Fang, P | 1 |
| Yang, S | 1 |
| Byelan, OV | 1 |
| Borzykh, OA | 1 |
| Mamontova, TV | 1 |
| Kaidashev, IP | 1 |
| Dixon, AE | 1 |
| Subramanian, M | 1 |
| DeSarno, M | 1 |
| Black, K | 1 |
| Lane, L | 1 |
| Holguin, F | 1 |
| Anderson, JR | 1 |
| Mortimer, K | 1 |
| Pang, L | 1 |
| Smith, KM | 1 |
| Bailey, H | 1 |
| Hodgson, DB | 1 |
| Shaw, DE | 1 |
| Knox, AJ | 1 |
| Harrison, TW | 1 |
| Park, SJ | 4 |
| Lee, KS | 4 |
| Kim, SR | 3 |
| Min, KH | 3 |
| Choe, YH | 1 |
| Moon, H | 1 |
| Chae, HJ | 1 |
| Yoo, WH | 1 |
| Lee, YC | 4 |
| Hwang, PH | 1 |
| Yi, HK | 1 |
| Song, CH | 1 |
| Chai, OH | 1 |
| Kim, JS | 1 |
| Lee, MK | 2 |
| Park, HS | 2 |
| Jin, SM | 2 |
| Kim, UH | 1 |
| Narala, VR | 1 |
| Ranga, R | 1 |
| Smith, MR | 1 |
| Berlin, AA | 1 |
| Standiford, TJ | 1 |
| Lukacs, NW | 1 |
| Reddy, RC | 1 |
| Hashimoto, Y | 1 |
| Nakahara, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma[NCT00994175] | Phase 2 | 15 participants (Actual) | Interventional | 2009-09-23 | Completed | ||
| A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics[NCT00634036] | Phase 2 | 23 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| PPAR-gamma: a Novel Therapeutic Target in Asthma?[NCT01134835] | Phase 4 | 68 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to safety concerns with pioglitazone) | ||
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics. (The GLITZ Asthma Study)[NCT00787644] | Phase 2 | 28 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to new safety concerns which emerged about pioglitazone during the trial) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Juniper Asthma Quality of Life Questionnaire (AQLQ) score at the end of the pioglitazone treatment period as compared to the placebo treatment period. The AQLQ is scored on a 7-point scale with 7 = not impaired at all, 1 = severly impaired (NCT00994175)
Timeframe: 16 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 4.7 |
| Placebo | 4.6 |
Juniper Asthma Quality of Life Questionnaire (AQLQ) score at the end of the pioglitazone treatment period as compared to the placebo treatment period. The AQLQ is scored on a 7-point scale with 7 = not impaired at all, 1 = severly impaired (NCT00994175)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 4.478 |
| Placebo | 4.306 |
Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test. PC20= Methacholine dose at wich the FEV1 deops by > 20% from pre-methacholine baseline values. (NCT00634036)
Timeframe: 12 weeks
| Intervention | mg/ml (Median) |
|---|---|
| Pioglitazone | 5.08 |
| Placebo | 2.37 |
(NCT00634036)
Timeframe: 12 weeks
| Intervention | ppb (Mean) |
|---|---|
| Pioglitazone | 27.6 |
| Placebo | 30.8 |
(NCT00634036)
Timeframe: 12 weeks
| Intervention | % predicted (Mean) |
|---|---|
| Pioglitazone | 80.3 |
| Placebo | 85.2 |
The Juniper Asthma Control Questionnaire is a validated scale ranging from 0 to 6. Higher scores represent poorer asthma control. Values > 1.5 are compatible with poorly controlled asthma (NCT00634036)
Timeframe: 12 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pioglitazone | 1.62 |
| Placebo | 1.82 |
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
"Airway reactivity will be measured with methacholine challenge testing following ATS guidelines.~This is the concentration of methacholine that produces a 20% decrease in lung function (measured by forced expiratory volume in 1 second)" (NCT00787644)
Timeframe: 12 weeks
| Intervention | mg/ml (Median) |
|---|---|
| 1. Pioglitazone | 5.08 |
| 2. Placebo | 2.37 |
4 trials available for pioglitazone and Asthma, Bronchial
| Article | Year |
|---|---|
A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.
Topics: Adult; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; M | 2017 |
[Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease].
Topics: Asthma; Cardiovascular Agents; Coronary Disease; Drug Monitoring; Drug Therapy, Combination; Endothe | 2015 |
A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.
Topics: Adult; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronch | 2015 |
Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
Topics: Adult; Aged; Asthma; Chemokine CCL2; Chemokine CXCL10; Double-Blind Method; Eosinophil Cationic Prot | 2016 |
7 other studies available for pioglitazone and Asthma, Bronchial
| Article | Year |
|---|---|
PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model.
Topics: Airway Remodeling; Animals; Asthma; MAP Kinase Signaling System; Mice; Ovalbumin; Pioglitazone; PPAR | 2018 |
Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.
Topics: Animals; Asthma; Disease Models, Animal; Down-Regulation; Female; Inflammation Mediators; Interleuki | 2009 |
PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eosinophils; Female; Gene Exp | 2005 |
Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eos | 2005 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
Topics: Anilides; Animals; Asthma; Chemokine CCL5; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Interc | 2006 |
Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma.
Topics: Allergens; Animals; Antigens, Plant; Asthma; Dexamethasone; Disease Models, Animal; Female; Mice; Mi | 2007 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; | 2002 |